Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Combined With Toripalimab in Pretreated Recurrent or Metastatic Cervical Cancer
NCT07363330Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in Cervical Cancer (CC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Objective Response Rate at 18 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07363330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363330.